BEAM - Beam Therapeutics Inc.

25.52
-1.920   -7.524%

Share volume: 2,087,868
Last Updated: 03-05-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$27.44
-1.92
-0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 8%
Dept financing 9%
Liquidity 43%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-11.05%
1 Month
-3.77%
3 Months
-5.83%
6 Months
27.98%
1 Year
-6.35%
2 Year
-33.33%
Key data
Stock price
$25.52
P/E Ratio 
0.00
DAY RANGE
$25.44 - $27.12
EPS 
-$0.90
52 WEEK RANGE
$13.52 - $36.44
52 WEEK CHANGE
-$10.39
MARKET CAP 
2.813 B
YIELD 
N/A
SHARES OUTSTANDING 
101.856 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
1.99
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,640,537
AVERAGE 30 VOLUME 
$1,886,433
Company detail
CEO: John Evans
Region: US
Website: beamtx.com
Employees: 510
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Beam Therapeutics Inc. develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders.

Recent news